Sanofi sells man­u­fac­tur­ing site to Re­ci­pharm; Ap­tose buys rights to sell Crys­talGe­nomic­s' can­cer drug in Chi­na

→ Sanofi is sell­ing off its con­tract res­pi­ra­to­ry drug man­u­fac­tur­ing site in the UK to Re­ci­pharm, which is pick­ing up man­u­fac­tur­ing ca­pac­i­ty as well as new clients in the $60 mil­lion deal. The plant’s 450 staffers will switch to their new em­ploy­er when the deal clos­es lat­er this year.

→ San Diego’s Ap­tose Bio­sciences $AP­TO has ex­pand­ed its li­cens­ing agree­ment with South Ko­rea’s Crys­talGe­nomics to sell the lat­ter com­pa­ny’s drug CG-806 in Chi­na, Macau, and Hong Kong. Ap­tose is pay­ing Crys­talGe­nomics $3 mil­lion up­front, with a to­tal deal val­ue of $125 mil­lion in­clud­ing mile­stones and roy­al­ties. CG-806 is a small mol­e­cule be­ing de­vel­oped for the treat­ment of acute myeloid leukemia, B-cell ma­lig­nan­cies, and ad­di­tion­al blood can­cers. Back in May, Ap­tose grabbed an ex­clu­sive li­cense from Crys­talGe­nomics to de­vel­op and com­mer­cial­ize CG-806 world­wide out­side of Chi­na and Ko­rea. This new deal ex­tends that li­cense agree­ment to in­clude Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER